Clinical trials
catalyst calendar across sponsors →Studies where RNTX is the lead sponsor, as filed with ClinicalTrials.gov. Completion dates are the sponsor's own projected windows and are revised as a study runs. Active studies first, then completed and stopped — newest readout first within each.
4 interventional · 1 with posted results
Held by 4 tracked-famous managers (CITADEL ADVISORS LLC, Qube Research & Technologies Ltd, Ancora Advisors LLC, RENAISSANCE TECHNOLOGIES LLC) · FINRA short interest 1.9 days to cover (settled 2026-07-31) · insider 90d: 3 buys / 0 sells · government filings 180d: none disclosed
| Study | Phase | Status | Interventions | Conditions | Enrollment | Primary completion | Readout in | Updated |
|---|---|---|---|---|---|---|---|---|
| A Phase 2 Study of LTI-03 in Patients With Idiopathic Pulmonary FibrosisNCT06968845Safety and Tolerability as measured by the incidence of treatment-emergent adverse events (TEAEs)Randomized · Triple-masked · Treatment | Phase 2 | Recruiting | Drug: LTI-03, Placebo · Device: Dry Powder Inhaler | Idiopathic Pulmonary Fibrosis (IPF) | 120 | 2027-09-30 | in 406 d | 2026-08-13 |
| A Study to Evaluate LTI-03 in Newly Diagnosed Idiopathic Pulmonary Fibrosis (IPF) PatientsNCT05954988results2025-07-31Incidence of Treatment-emergent Adverse Events (TEAEs)Randomized · Quadruple-masked · OtherStudy Protocol ↗ · Statistical Analysis Plan ↗ | Phase 1 | Completed | Drug: LTI-03, Placebo | Idiopathic Pulmonary Fibrosis | 24 | 2024-09-25actual | — | 2025-07-31 |
| A Study to Evaluate LTI-01 in Patients With Infected, Non-draining Pleural EffusionsNCT04159831Incidence of referral to surgeryRandomized · Quadruple-masked · Treatment | Phase 2 | Completed | Drug: LTI-01, Placebo | Pleural Effusion | 44 | 2022-03-31actual | — | 2023-03-30 |
| Safety, Tolerability and Pharmacokinetic Study of LTI-03 in Healthy Adult SubjectsNCT04233814Incidence of Treatment-Emergent Adverse Events (TEAE)Randomized · Triple-masked · Other | Phase 1 | Completed | Drug: Caveolin-1-Scaffolding-Protein-Derived Peptide (LTI-03), Placebo | Idiopathic Pulmonary Fibrosis | 71 | 2021-12-23actual | — | 2022-03-07 |
Primary completion is the date the sponsor filed with the registry — their own projection, revised whenever they revise it, unless the row is marked actual.
Source: ClinicalTrials.gov, retrieved 2026-08-19